Literature DB >> 10762159

Thalamic involvement in neurofibromatosis type 1: evaluation with proton magnetic resonance spectroscopic imaging.

P Y Wang1, W E Kaufmann, C W Koth, M B Denckla, P B Barker.   

Abstract

Neurofibromatosis type 1 is a common autosomal dominant disorder associated with learning disabilities. In addition to gliomas and other tumors, T2 hyperintense lesions (unidentified bright objects or UBOs) are frequently found in the globus pallidus, cerebellum, and white matter regions. To better characterize supratentorial UBO functional significance, we studied by quantitative magnetic resonance spectroscopic imaging (MRSI) 9 male subjects with neurofibromatosis type 1 (age, 6-19 years) and 9 age-matched and sex-matched controls. Maps of the anatomical distribution of the metabolites choline (Cho), N-acetylaspartate (NAA), and creatine were calculated in four axial 15-mm slices. Absolute metabolite concentrations within UBOs, unaffected globus pallidus, and thalami demonstrated an age-related pattern, characterized by elevated Cho and relatively preserved NAA in younger subjects (<10 years) and reduced NAA and normal Cho in older subjects. These changes were found in both UBOs and thalami but were only significant for NAA, NAA/creatine, and NAA/Cho in the latter region. Decreases in NAA ratios were most severe in the thalami of subjects with UBOs in the globus pallidus, whereas UBOs showed similar but milder abnormalities than those in the thalamus. We speculate that the MRSI metabolic abnormality may represent a more generalized phenomenon, without a T2 signal counterpart in the affected brain regions. Based on the neuropathological study by DiPaolo and colleagues (1995), we postulate that Cho elevations reflect increased myelin turnover in areas of intramyelinic edema, which is followed by neuropil injury (reduced NAA). Temporal progression and behavioral correlates of these MRSI changes deserve further exploration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10762159

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  10 in total

1.  Proton magnetic resonance spectroscopy in childhood brainstem lesions.

Authors:  L Porto; E Hattingen; U Pilatus; M Kieslich; B Yan; D Schwabe; F E Zanella; H Lanfermann
Journal:  Childs Nerv Syst       Date:  2006-09-16       Impact factor: 1.475

2.  Prospective evaluation of the brain in asymptomatic children with neurofibromatosis type 1: relationship of macrocephaly to T1 relaxation changes and structural brain abnormalities.

Authors:  R G Steen; J S Taylor; J W Langston; J O Glass; V R Brewer; W E Reddick; R Mages; E K Pivnick
Journal:  AJNR Am J Neuroradiol       Date:  2001-05       Impact factor: 3.825

3.  T2 hyperintensities in children with neurofibromatosis type 1 and their relationship to cognitive functioning.

Authors:  Shelley L Hyman; Deepak S Gill; Edwin Arthur Shores; Adam Steinberg; Kathryn N North
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-02-13       Impact factor: 10.154

4.  Proton MR spectroscopic imaging of basal ganglia and thalamus in neurofibromatosis type 1: correlation with T2 hyperintensities.

Authors:  Charlotte Barbier; Camille Chabernaud; Laurent Barantin; Philippe Bertrand; Catherine Sembely; Dominique Sirinelli; Pierre Castelnau; Jean-Philippe Cottier
Journal:  Neuroradiology       Date:  2010-10-20       Impact factor: 2.804

5.  Multivariate pattern analysis reveals subtle brain anomalies relevant to the cognitive phenotype in neurofibromatosis type 1.

Authors:  João V Duarte; Maria J Ribeiro; Inês R Violante; Gil Cunha; Eduardo Silva; Miguel Castelo-Branco
Journal:  Hum Brain Mapp       Date:  2012-09-11       Impact factor: 5.038

6.  Quantitative differentiation between healthy and disordered brain matter in patients with neurofibromatosis type I using diffusion tensor imaging.

Authors:  S J P M van Engelen; L C Krab; H A Moll; A de Goede-Bolder; S M F Pluijm; C E Catsman-Berrevoets; Y Elgersma; M H Lequin
Journal:  AJNR Am J Neuroradiol       Date:  2008-03-13       Impact factor: 3.825

7.  Evaluation of the basal ganglia in neurofibromatosis type 1.

Authors:  Francesco Nicita; Claudio Di Biasi; Saadi Sollaku; Stefano Cecchini; Vincenzo Salpietro; Angelo Pittalis; Laura Papetti; Fabiana Ursitti; Fiorenza Ulgiati; Anna Maria Zicari; Gian Franco Gualdi; Enrico Properzi; Marzia Duse; Martino Ruggieri; Alberto Spalice
Journal:  Childs Nerv Syst       Date:  2013-07-27       Impact factor: 1.475

8.  GABA deficiency in NF1: A multimodal [11C]-flumazenil and spectroscopy study.

Authors:  Inês R Violante; Miguel Patricio; Inês Bernardino; José Rebola; Antero J Abrunhosa; Nuno Ferreira; Miguel Castelo-Branco
Journal:  Neurology       Date:  2016-07-29       Impact factor: 9.910

9.  Gyrification, cortical and subcortical morphometry in neurofibromatosis type 1: an uneven profile of developmental abnormalities.

Authors:  Inês R Violante; Maria J Ribeiro; Eduardo D Silva; Miguel Castelo-Branco
Journal:  J Neurodev Disord       Date:  2013-02-13       Impact factor: 4.025

10.  Age-related change in brain metabolite abnormalities in autism: a meta-analysis of proton magnetic resonance spectroscopy studies.

Authors:  Y Aoki; K Kasai; H Yamasue
Journal:  Transl Psychiatry       Date:  2012-01-17       Impact factor: 6.222

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.